NLS Pharmaceutics Ltd. Warrant
NLSPW
About: NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
Employees: 1
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
50% more capital invested
Capital invested by funds: $1.14K [Q1] → $1.71K (+$572) [Q2]
2.52% more ownership
Funds ownership: 0.22% [Q1] → 2.74% (+2.52%) [Q2]
0% more funds holding
Funds holding: 3 [Q1] → 3 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Financial journalist opinion
We haven’t received any recent news articles for NLSPW